Calcitonin gene-related peptide receptor antagonist

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of drugs that act as antagonists of the calcitonin gene-related peptide receptor (CGRPR).

CGRPR antagonists are under investigation as potential antimigraine agents and also in the context of osteoarthritis.[1]

Examples

Most experimental CGRP inhibitors are monoclonal antibodies[5] given by monthly injections.[5]

Clinical trials

In June 2015 Phase 2 clinical trial data for three different anti-CGRP drugs ( Amgen (AMG 334), Teva Pharmaceuticals (TEV-48125), and Eli Lilly & Co (LY2951742)) were presented at the American Headache Society's (AHS) annual meeting.[5]

In March 2016 Alder reported phase IIb clinical trial data for its ALD403.[6]

By April 2016, Alder, Amgen and Teva had initiated phase III trials.[7]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  5. ↑ 5.0 5.1 5.2 New Data on CGRP Monoclonal Antibodies for Migraine Prevention. June 2015
  6. ↑ Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine. March 2016
  7. ↑ Can Alder Beat Teva And Amgen In Treating Migraines? Will Positive Phase III Data Help Keryx's Auryxia Receive Approval For An Expanded Indication? April 2016


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Calcitonin_gene-related_peptide_receptor_antagonist&oldid=714349307"